Selection of hypertrophic cardiomyopathy patients for myectomy or alcohol septal ablation

Anadolu Kardiyoloji Dergisi

Volumn 6, Issue SUPPL. 2, 2006, Pages 27-30

  Lever, Harry M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Myectomy

Indexed keywords

ALCOHOL; CONTRAST MEDIUM;

ALCOHOL SEPTUM ABLATION; ANGIOCARDIOGRAPHY; AORTA VALVE REGURGITATION; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; COMORBIDITY; ECHOCARDIOGRAPHY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART INFARCTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SEPTUM MYECTOMY; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; LENGTH OF STAY; MITRAL VALVE REGURGITATION; MORBIDITY; NONSURGICAL INVASIVE THERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE INFECTION; POSTOPERATIVE PAIN; REVIEW; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SURGICAL MORTALITY; SURGICAL RISK; SURGICAL TECHNIQUE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT INDICATION;

CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; HEART SEPTUM; HUMANS; PATIENT SELECTION;

EID: 33846263997     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;20:1-18.
2. Brock R. Functional obstruction of the left ventricle. Guy's Hosp Rep 1957;106:221-38.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
4. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
5. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyapathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
6. Maron MS IO, Zenovich AG, Udelsn JE, Link MS, Pandian NG, Kuvin JT, et al. Evidence that hypertrophic cardiomyopathy is a disease characterized by predominately left ventricular outflow tract obstruction. J Am Coll Cardiol 2005;45 (Suppl):161A (abstr).
7. Jiang L, Levine RA, King ME, Weyman AE. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987;113:633-44.
8. Wigle ED, Adelman AG, Auger P, Marquis Y. Mitral regurgitation in muscular subaortic stenosis. Am J Cardiol 1969;24:698-706.
9. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1-83.
10. Schwammenthal E, Nakatani S, He S, Hopmeyer J, Sagie A, Weyman AE, et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 1998;98:856-65.
11. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20:42-52.
12. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219-25.
13. Adelman AG, Wigle ED, Ranganathan N, Webb GD, Kidd BS, Bigelow WG, et al. The clinical course in muscular subaortic stenosis. A retrospective and prospective study of 60 hemodynamically proved cases. Ann Intern Med 1972;77:515-25.
14. Shah PM, Gramiak R, Adelman AG, Wigle ED. Echocardiographic assessment of the effects of surgery and propranolol on the dynamics of outflow obstruction in hypertrophic subaortic stenosis. Circulation 1972;45:516-21.
15. Maron BJ, Bonow RO. Cannon RO, 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987;316:780-9.
16. Maron BJ, Bonow RO, Cannon RO, 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 1987;316:844-52.
17. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation 1968;38:845-58.
18. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979;42:35-42.
19. Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 1981;48:545-53.
20. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251-8.
21. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988;62:1085-8.
22. Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988;62:1248-51.
23. Pollick C. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am J Cardiol 1988;62:1252-5.
24. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-8.
25. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342-54.
26. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH, 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000;36:852-5.
27. Levine RA, Vlahakes GJ, Lefebvre X, Guerrero JL, Cape EG, Yoganathan AP, et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 1995;91:1189-95.
28. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36:1344-54.
29. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 1991;84:1188-97.
30. Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978;57:1205-13.
31. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6.
32. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum F, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-41.
33. Smedira NG LH, Miluk M, Krishnaswamy G, Laing G, Thamilarasan M, Lytle BW, et al. Septal Myectomy: 324 consecutive procedures without a mortality. J Am Coll Cardiol 2006;47 (Suppl):275A (abstr).
34. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;20:1066-72.
35. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994-2000.
36. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
37. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - the Baylor experience (1996-2002). Clin Cardiol 2005;28:124-30.
38. Seggewiss H, Faber L, Gieichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
39. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, et al. Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol 2005;94:516-23.
40. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005;129:351-8.
41. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-24.
42. Batalis NI, Harley RA, Collins KA. Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: case reports and an approach to the autopsy and death certification. Am J Forensic Med Pathol 2005;26:343-8.
43. Simon RD, Crawford FA, 3rd, Spencer WH 3rd, Gold MR. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005;28:1354-6.
44. Boltwood CM, Jr., Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 2004;351:1914-5.
45. Crawford FA III KD, Franklin J, Spencer WH, Gold MR. Implantable cardioverter-defibrillators for primary prevention of sudden cadiac death in patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation. Circulation 2003;108(suppl IV):IV386-7.